menu
    • menu
    [{"orgOrder":0,"company":"Midatech Pharma","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Panobinostat lactate","moa":"HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Midatech Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Midatech Pharma \/ H.C. Wainwright","highestDevelopmentStatusID":"6","companyTruncated":"Midatech Pharma \/ H.C. Wainwright"},{"orgOrder":0,"company":"Midatech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Panobinostat lactate","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Midatech Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Midatech Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Midatech Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Midatech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Panobinostat lactate","moa":"HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Midatech Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Midatech Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Midatech Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Midatech Pharma","sponsor":"Midatech Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Merger","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Midatech Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Midatech Pharma \/ Midatech Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Midatech Pharma \/ Midatech Pharma"},{"orgOrder":0,"company":"Midatech Pharma","sponsor":"Bioasis","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2023","type":"Termination","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Midatech Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Midatech Pharma \/ Midatech Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Midatech Pharma \/ Midatech Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Midatech Pharma

    Menu

    Midatech Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Midatech Pharma

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed

                            Midatech Pharma

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Bioasis

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc

                            Details : Bioasis Technologies is developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous sys...

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            January 23, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Bioasis

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Midatech Pharma

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed

                            Midatech Pharma

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Biodexa Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Bioasis Technologies Inc. Announces Merger with Midatech Pharma plc

                            Details : Bioasis Technologies is developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous sys...

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            December 13, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Biodexa Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Midatech Pharma

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed

                            Midatech Pharma

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Panobinostat lactate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Patient Enrolled in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma

                            Details : MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl-β-cyclodextrin (HPBCD), that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour.

                            Brand Name : MTX110

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 14, 2022

                            Lead Product(s) : Panobinostat lactate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Midatech Pharma

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed

                            Midatech Pharma

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Panobinostat lactate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Midatech Pharma PLC Announces Headline Results of MTX110 Phase I DIPG Study

                            Details : The study has determined a proposed dose range for MTX110 for Phase II and has shown that repeated delivery of MTX110 via CED is feasible and safe.

                            Brand Name : MTX110

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 19, 2020

                            Lead Product(s) : Panobinostat lactate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Midatech Pharma

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed

                            Midatech Pharma

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Panobinostat lactate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : H.C. Wainwright

                            Deal Size : $3.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Midatech Raises USD3 Million, Plans To Raise Further GBP1.8 Million

                            Details : The cash raised will be used to fund Midatech's MTX110 clinical programme, the development of an internal pipeline of Q-Sphera formulations for partnering, and for general corporate purposes.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 18, 2020

                            Lead Product(s) : Panobinostat lactate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : H.C. Wainwright

                            Deal Size : $3.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth